Search Results - immunotherapy

44 Results

Sort By:

Single-Chain Bispecific Chimeric Antigen Receptor Targeting BCMA and CS1 for the Treatment of Multiple Myeloma (UCLA Case No. 2018-680)

UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a single-chain bispecific chimeric antigen receptor targeting BCMA and CS1 for treating multiple myeloma. BACKGROUND: Multiple myeloma (MM) is a cancer of the plasma cells that accounts for over 30,000 new diagnoses each year, according to the American Cancer...

Published: 2/19/2025 | Inventor(s): Yvonne Chen, Eugenia Zah

Keywords(s): Hematology, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Therapeutics > Immunology And Immunotherapy, Therapeutics > Hematology

3D Scaffold for T Cell Delivery and Suppression of Tregs for Solid Tumors (UCLA Case No. 2020-193)

SUMMARY: UCLA researchers in the Department of Bioengineering have developed a small and biodegradable implant that when placed adjacent to solid tumors, enhances immune response to cancer cells. BACKGROUND: The body’s immune system uses proteins called antibodies to train the immune response to foreign pathogens. This mechanism can combat...

Published: 2/14/2025 | Inventor(s): Manish Butte

Keywords(s): cytokines, Drug Delivery, Immunotherapy, Nanoparticles, scaffolds, solid tumors, T-cell activation, t-cells

Category(s): Platforms > Drug Delivery > Nanoparticles

An Alternative T Cell Redirecting Bispecific Antibody Against Human Cytomegalovirus (UCLA Case No. 2024-198)

UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have created a novel T cell redirecting bispecific antibody (TRBA) for treatment of cytomegalovirus (CMV) infection. BACKGROUND: The human cytomegalovirus (CMV) has a seroprevalence of about 60% in the USA and nearly 100% of the population in some parts of the world....

Published: 2/14/2025 | Inventor(s): Otto Yang

Keywords(s): Anti-CD3 antibodies, Bispecific antibodies, CD8 T cells, Human cytomegalovirus (CMV), immunocompromised patients, Immunotherapy, Lymphocytes, T cell redirecting bispecific antibody (TRBA), Transplant, Viral infection

Category(s): Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy

Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)

UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...

Published: 2/14/2025 | Inventor(s): Roger Lo

Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)

UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced immunotherapy efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...

Published: 2/14/2025 | Inventor(s): Bin Liu, Steven Dubinett

Keywords(s): anti-tumor immunity, cell-based therapy, Immune checkpoint blockade, Immunotherapy, non-small cell lung cancer, treatment resistance, Tumor microenvironment, Vaccines

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Respiratory And Pulmonary

Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant Glioma Patients (UCLA Case No. 2024-043)

UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...

Published: 2/14/2025 | Inventor(s): Robert Prins

Keywords(s): adjuvant therapy, Biomarker, Chemotherapy, Clinical Trial, dendritic cell vaccination, Glioblastoma, Glioma, immune response, Immunotherapy, interferon, malignant glioma

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Oncology, Therapeutics > CNS and Neurology

Affinity and Functional Based Screening of T Cell Receptor Repertoire Using Nanovials (Case No. 2024-042)

Summary: Researchers in the Department of Bioengineering at UCLA have developed a hydrogel platform that measures single T cell secretions, aiding in the definition of T cell receptor repertoires for functional immunotherapy applications. Background: T cell immunotherapies, namely T cell receptor (TCR) therapies, have emerged as promising candidates...

Published: 2/14/2025 | Inventor(s): Dino Di Carlo, Owen Witte, Doyeon Koo, Zhiyuan Mao

Keywords(s): Cancer Immunotherapy, CAR-T cell therapy, Flow Cytometry, hydrogel, Immunooncology, Immunotherapy, Peptide, single cell analysis, T Cell, T cell based therapy

Category(s): Diagnostic Markers > Immunology, Life Science Research Tools > Screening Libraries, Therapeutics > Immunology And Immunotherapy

Methods and Compositions for Treating Melanoma (UCLA Case No. 2021-324)

The Graeber Laboratory at UCLA discovered a novel mechanism for treating melanoma using ferroptosis, a type of programmed cell death, that shows promise against therapy resistance. BACKGROUND: Melanoma is a highly aggressive skin cancer that spreads throughout the body and can be fatal if left untreated. Therapies for melanoma range from immunotherapy...

Published: 2/14/2025 | Inventor(s): Thomas Graeber

Keywords(s): Cancer, ferroptosis, Immunotherapy, MAPK signaling, Melanoma, Oncology, Skin, tumor resistance

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Engineered T Cells Capable of Simultaneous Tumor Targeting and Alteration of Tumor Microenvironment Through Vasculature Normalization (UCLA Case No. 2023-264)

UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have built a series of chimeric antigen receptor (CAR)-T cells that target different antigens and secrete different anti-angiogenic proteins. Additionally, researchers also constructed bispecific CARs that respond to tumor antigen and pro-angiogenic molecules. BACKGROUND:...

Published: 2/14/2025 | Inventor(s): Yvonne Chen

Keywords(s): Cancer, Cancer Immunotherapy, CAR-T cell therapy, immunosuppression, Immunosuppressive Drug, Immunotherapy, solid tumors, Tumor microenvironment, tumor vasculature, VEGF

Category(s): Therapeutics > Oncology

Targeting Serotonin Transporter (SERT) for Cancer Immunotherapy (UCLA Case No. 2024-204)

UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have unveiled a novel therapeutic strategy utilizing SSRIs for solid cancer immunotherapy. BACKGROUND: Immunotherapy has become a highly effective method to combat cancer that enhances a patient’s immune system to attack tumors with high specificity. For instance,...

Published: 2/14/2025 | Inventor(s): Lili Yang

Keywords(s): Cancer, Immune checkpoint blockade, immune checkpoint inhibitors, Immunotherapy, selective serotonin reuptake inhibitors (SSRIs), serotonin, solid tumors, T Cell

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

1 2 3 4 5